DexCom resumed with a Buy at Stifel

Stifel analyst Jonathan Block resumed coverage of DexCom (DXCM) with a Buy rating and $85 price target The firm’s due diligence was “upbeat” for the Continuous Glucose Monitor market in general and “particularly bullish” for DexCom specifically, the analyst tells investors. The company’s 15-day sensor was “the standout among CGM innovations” and checks suggest investors’ perceived G7 issues are “not top of mind” among endocrinologists or primary care physicians, the analyst added.